Clearbridge Health (SGX:1H3) narrowed its attributable loss in the first half of 2025 to SG$1.4 million from SG$2.2 million a year earlier, according to a Thursday filing with the Singapore Exchange.
Loss per share stood at SG$0.0008 compared with SG$0.0038 in the comparable period.
Revenue was up 8% year over year to SG$4.9 million from SG$4.5 million, mainly due to increased revenue from renal care services provided in the Philippines.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。